Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.83 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753388 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL8409352 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL3017103 | 0.94 | MRGPRX2 (0.89) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL2171816 | 0.94 | MRGPRX2 (0.89) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL6754812 | 0.91 | OPRM1 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13268600 | 0.91 | OPRM1 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL152647 | 0.91 | OPRM1 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL1743681 | 0.91 | OPRM1 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13245908 | 0.91 | OPRM1 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13267437 | 0.91 | OPRM1 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240230633-A1 | ENZYME-CONJUGATED MAGNETIC BEADS SUSPENDED IN INTERNAL STANDARD BUFFER | DH TECHNOLOGIES DEV PTE LTD (SG) | 2024-07-11 | — | — | US | claimed |
| CN-118222544-A | Short spirochete beta-glucuronidase and application thereof | 麒牛药业(珠海横琴)有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20240168040-A1 | BIOLOGICAL SAMPLE PREPARATION AND ANALYSIS | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2024-05-23 | — | — | US | claimed |
| EP-4314823-A1 | BIOLOGICAL SAMPLE PREPARATION AND ANALYSIS | DH Technologies Development Pte. Ltd. (SG) | 2024-02-07 | — | — | EP | claimed |
| CN-117120845-A | Biological sample preparation and analysis | DH科技发展私人贸易有限公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2022248979-A1 | ENZYME-CONJUGATED MAGNETIC BEADS SUSPENDED IN INTERNAL STANDARD BUFFER | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2022-12-01 | — | — | WO | claimed |
| WO-2022201000-A1 | BIOLOGICAL SAMPLE PREPARATION AND ANALYSIS | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2022-09-29 | — | — | WO | claimed |
| US-5908927-A | Synthesis of deuterated opiate glucuronides | HIGH STANDARD PRODUCTS CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| US-12614709-B2 | Workflow for high-throughput analysis of analytes in liquid samples | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2026-04-28 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12509469-B2 | Compositions and methods for the treatment of pain and dependence disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-12-30 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| US-20060019400-A1 | Method for the determination of glucuronides in physiological samples | UNIVERSITY OF MARYLAND (US) | 2006-01-26 | — | — | US | disclosed |
| US-6262265-B1 | ANALOGS CAN BE MADE TO CONTAIN PROTEIN REACTIVE GROUPS, USED TO FORM PROTEIN CONJUGATES, FLUORESCENTLY LABELED COMPOUNDS, SOLID-PHASE ADSORBANTS; ANTIBODIES CAN BE USED IN COMBINATION WITH LABELED ANALOGS SUITABLE FOR TESTING HEROIN ABUSE | MICROGENICS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| WO-2000078763-A2 | NON-HYDROLYZABLE ANALOGS OF HEROIN METABOLITES SUITABLE FOR USE IN IMMUNOASSAY | MICROGENICS CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6124282-A | Drug formulations | SELLERS EDWARD M (CA) | 2000-09-26 | — | — | US | disclosed |
| EP-0793664-A1 | MORPHINE AND CODEINE DERIVATIVES FOR USE IN THERAPY | BTG INTERNATIONAL LIMITED (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016063-A1 | MORPHINE AND CODEINE DERIVATIVES FOR USE IN THERAPY | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | MRGPRX2 1275/4885OPRM1 4810/4885OPRD1 4518/4885 |
| US-12509469-B2 | Compositions and methods for the treatment of pain and dependence disorders | OPRD1, OPRL1, OPRM1 | MRGPRX2 469/4885OPRM1 3/4885OPRD1 1/4885 |
| US-12614709-B2 | Workflow for high-throughput analysis of analytes in liquid samples | SRMS, HAMP, SLCO1A2 | MRGPRX2 4828/4885OPRM1 2433/4885OPRD1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.